Month: February 2021

Lucira Health Announces Closing of its Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of...

Asia Green Biotechnology Corp. Expands Technology Development Relationship with Pathway Rx Inc. and Swysh Inc. with Agreement to Undertake Initial Toxicity Testing for Migraine Study

Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China

DURHAM, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company...

Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors

With Encouraging Safety and Anti-tumor Activity for AO-176 Monotherapy in Phase 1 Trial, Advancing AO-176 in Combination with Anti-PD-1BRISBANE, Calif....

error: Content is protected !!